Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00634400
First received: March 7, 2008
Last updated: January 24, 2011
Last verified: January 2011

March 7, 2008
January 24, 2011
March 1999
May 2003   (final data collection date for primary outcome measure)
Cardiovascular mortality or hospitalisation due to congestive heart failure [ Time Frame: 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months ]
Same as current
Complete list of historical versions of study NCT00634400 on ClinicalTrials.gov Archive Site
Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI [ Time Frame: 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months ]
Same as current
Not Provided
Not Provided
 
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)
Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function

A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Congestive Heart Failure
  • Drug: Candesartan
    Other Name: Atacand
  • Drug: Placebo
    Other Name: Placebo
  • Active Comparator: 1
    Intervention: Drug: Candesartan
  • Placebo Comparator: 2
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6268
May 2003
May 2003   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female aged 18 or above
  • Congestive Heart Failure with symptoms for more than 4 weeks before starting study
  • Provision of informed consent

Exclusion Criteria:

  • Current low blood pressure with symptoms
  • Liver disease considered significant by the study doctor
  • Pregnant or lactating females
Both
18 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00634400
SH-AHS-0003, D2454C00003
No
Not Provided
AstraZeneca
Not Provided
Principal Investigator: Chris Granger, MD
AstraZeneca
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP